| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Nrf2 activator-21 (Compound 7I) (1-15 μM, 24 h) significantly improved the survival rate of hippocampal neurons exposed to H2O2[1]. Nrf2 activator-21 (2.5 μM, 24 h) reduced hippocampal neuronal apoptosis and decreased caspase-3 activity[1].
|
|---|---|
| ln Vivo |
Nrf2 activator-21 (Compound 7I) (15 mg/kg, intraperitoneal injection, single dose, 15 minutes after reperfusion) significantly improved neurological function in state Wistar vein double vessel occlusion (2VO) induced cerebral ischemia/reperfusion injury [1].
|
| Cell Assay |
Apoptosis Analysis[1]
Cell Types: hippocampal neurons Tested Concentrations: 2.5 μM Incubation Duration: 24 h Experimental Results: Reduced apoptosis and decreased caspase-3 activity in the hippocampal neurons. |
| Animal Protocol |
Animal/Disease Models: Male adult Wistar rats: a midline neck incision was made to isolate bilateral common carotid arteries, which were then clamped simultaneously for 15 min to induce cerebral ischemia, followed by 15 min of reperfusion to establish the 2-vessel occlusion (2VO) cerebral ischemia/reperfusion injury model[1]
Doses: 15 mg/kg Route of Administration: i.p. once 15 min post-reperfusion Experimental Results: Achieved significant improvements in motor function, sensory response, and wire cage climbing ability, with total neurological deficit scores notably reduced in 2VO model rats. Showed alleviation of anxiety-like behavior. Improved memory function, with the discrimination index significantly increased in the Novel Object Recognition Test, reversing memory deficits induced by cerebral ischemia/reperfusion injury . Preserved hippocampal CA1 neuron morphology and reduced the number of degenerated dark neurons and decreased hippocampal caspase-3 activity. Increased hippocampal Nrf2 protein expression, restored SOD and CAT activities to near-sham levels and reduced MDA levels . Upregulated hippocampal BDNF and TrkB receptor levels and enhanced neuroprotective signaling. |
| References |
| Molecular Formula |
C19H14O5
|
|---|---|
| Molecular Weight |
322.31
|
| CAS # |
1912404-14-8
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1026 mL | 15.5130 mL | 31.0260 mL | |
| 5 mM | 0.6205 mL | 3.1026 mL | 6.2052 mL | |
| 10 mM | 0.3103 mL | 1.5513 mL | 3.1026 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
